Clinical trials: Liver Dysfunction, open to volunteers
Type 2 Diabetes, Metabolic Dysfunction-Associated Steatotic Liver Disease
Liver Fibrosis Assessment in Diabetic Patients
The investigators plan to use the smartphone App for FIB-4 calculation and increase the awareness of liver fibrosis. These patients might notify and discuss with the physician of their liver fibrosis severity to improve the…
- Trial name
- NCT06694974
- Testing
- APP calculation for FIB-4, Standard Care (in control arm)
- Where
- Taiwan
- Volunteers
- 540 people
- Sponsor
- National Taiwan University Hospital
Metabolic Dysfunction Associated Steatotic Liver Disease
Assessment of Circulating Leptin Levels in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease
This study aims to evaluate circulating leptin levels in patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Leptin is an adipokine involved in metabolism and inflammation.
- Trial name
- NCT07873749
- Testing
- Serum Leptin Measurement
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Sohag University
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD
This study will test a study drug called ALN-PNP with and without another drug that is used for controlling blood sugar, appetite, and weight (for example, tirzepatide), to see if it can help treat MASLD, also known as fatty…
- Trial name
- NCT07527910
- Testing
- ALN-PNP, Tirzepatide
- Where
- 9 sites in United States
- Volunteers
- 204 people
- Sponsor
- Regeneron Pharmaceuticals
Metabolic Dysfunction-associated Fatty Liver Disease, Hepatic Steatosis
Association of HsCAR with MAFLD and Liver Fibrosis: a Cross-sectional Study
The goal of this observational study is to investigate the associations between a novel inflammatory marker, high sensitivity C-reactiveprotein to albumin ratio (hsCAR), and steatosis and fibrosis of metabolic…
- Conditions
- Metabolic Dysfunction-associated Fatty Liver Disease, Hepatic Steatosis, Liver Fibrosis
- Trial name
- NCT05974904
- Testing
- high-sensitivity C-reactive protein to albumin ratio
- Where
- China
- Volunteers
- 7,000 people
- Sponsor
- Chongqing Medical University
Liver Transplantation, Liver Graft Dysfunction
Tissue Microdialysis Monitoring of Liver Grafts
This study will investigate the dynamics of metabolic molecules sampled from human liver grafts during the early postoperative period using tissue microdialysis.
- Conditions
- Liver Transplantation, Liver Graft Dysfunction, Tissue Metabolism
- Trial name
- NCT06890234
- Where
- Slovenia
- Volunteers
- 25 people
- Sponsor
- University Medical Centre Ljubljana
Aspergillosis Invasive
Liposomal Amphotericin B in Invasive Aspergillosis With Hepatic Dysfunction
Liposomal amphotericin B is an antifungal agent commonly used to treat invasive aspergillosis, a severe fungal infection associated with high mortality in critically ill patients.
- Trial name
- NCT07337720
- Testing
- LIposomal amphotericin B (L-AmB) treatment
- Volunteers
- 40 people
- Sponsor
- Southeast University, China
MAFLD in Prediabetes and Diabetes
Effect of SGLT2 Inhibitor on Metabolic-Dysfunction-Associated Fatty Liver Disease in Patients With Insulin Resistance
Metabolic-dysfunction-associated fatty liver disease (MAFLD) has evolved as a major health problem recently. Discovering ways to prevent or delay the progression of MAFLD has become a global focus.
- Trial name
- SGLT2 (NCT07891234)
- Testing
- Dapagliflozin 5Mg Tab, Metfomin 500 mg, Dapagliflozin (10mg Tab)
- Where
- Egypt
- Volunteers
- 66 people
- Sponsor
- Sherihan AboElyazed Mohamed Khalil
Metabolic Dysfunction-Associated Steatotic Liver Disease, People Living With HIV
Effect on Body Weight Reduction of a Behavioral Intervention on Lifestyle Using a Digital Nutritional Program in People Living With HIV and Metabolic Dysfunction-associated Steatotic Liver Disease
Metabolic dysfunction-associated steatotic liver disease (MASLD) is now the leading cause of chronic liver disease in people living with HIV (PLWH). Currently, there are no approved medications to treat this condition.
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease, People Living With HIV, Life Style
- Trial name
- APEVI (NCT07456332)
- Testing
- Digital nutritional program, Standard care dietary and exercice advice.
- Where
- Spain
- Volunteers
- 116 people
- Sponsor
- Hospital Universitari de Bellvitge
Metabolic Dysfunction-associated Steatotic Liver Disease, Type 2 Diabetes Mellitus
Henagliflozin on Liver Fibrosis in Patients with MASLD and T2DM
The prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) is increasing due to changes in economic conditions and lifestyle, and it is anticipated to become a significant liver disease burden in the…
- Trial name
- NCT06762223
- Testing
- Henagliflozin 10 mg daily, Metformin 1700 mg daily
- Where
- China
- Volunteers
- 190 people
- Sponsor
- Xiqiao Zhou
Metabolic Dysfunction-Associated Steatoic Liver Disease
Vitamin E Versus Silymarin in Non Diabetic MASLD Patients
MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease), is a chronic liver condition marked by excessive fat buildup (steatosis) in liver cells, linked to at least one metabolic risk factor like obesity, type 2…
- Trial name
- MASLD (NCT07863648)
- Testing
- Vitamin E 800 IU/d, Silymarin 420 mg
- Where
- Egypt
- Volunteers
- 120 people
- Sponsor
- Kafrelsheikh University
Metabolic Dysfunction-Associated Steatotic Liver Disease Infant Development
TUDCA in High-Risk Lactating Mothers Identified by Early Postpartum Milk Hydrophobicity Index
This is a randomized, double-blind, placebo-controlled Phase 2 proof-of-concept trial in mother-infant dyads. The study aims to evaluate the safety, tolerability, and biological effects of maternal oral tauroursodeoxycholic acid…
- Trial name
- MILK-HI-TUDCA (NCT07517276)
- Testing
- tauroursodeoxycholic acid (TUDCA)
- Volunteers
- 80 people
- Sponsor
- Peking University First Hospital
Metabolic Dysfunction-Associated Liver Disease
Type 2 DIAbeTes With NAFLD: innOvative Biomarkers of Disease progressioN and clInical outComes
Type 2 diabetes (T2DM) patients are at high-risk for advanced fibrosis (AF) due to non-alcoholic fatty liver disease (NAFLD), recently renamed Metabolic dysfunction-Associated Liver Disease (MASLD).
- Trial name
- DIATONIC (NCT06567990)
- Testing
- Non-invasive test for the screening of MASLD-related advanced fibrosis in patients with T2D.
- Where
- 4 sites in France
- Volunteers
- 500 people
- Sponsor
- Hospices Civils de Lyon
Fatty Liver Disease
Synbiotics Impact on Insulin and TNF-α in MAFLD: a Gut Microbiota Profile Analysis
Primary Objective: To analyze the effect of synbiotic supplementation on metabolic profile, insulin and TNF-α and gut microbiota changes in patients with Metabolic dysfunction-Associated Fatty Liver Disease (MAFLD).
- Trial name
- NCT06585982
- Testing
- Treatment, Control
- Where
- Indonesia
- Volunteers
- 50 people
- Sponsor
- Universitas Diponegoro
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
The Effect of the DASH Diet on Clinical and Metabolic Parameters in Children With MASLD
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in childhood is becoming increasingly prevalent, paralleling the rise in obesity rates, and has become the most common chronic liver disease in the pediatric…
- Trial name
- NCT07480811
- Testing
- DASH Diet, Standart Diet, Physical Activity
- Volunteers
- 88 people
- Sponsor
- Antalya Training and Research Hospital
MASH - Metabolic Dysfunction-Associated Steatohepatitis, MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease)
AGED Diagnostics Clinical Validation Study
Validation of Blood-Based Tests for the Diagnosis of Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Liver Fibrosis: This study aims to validate two investigational blood tests developed by AGED Diagnostics for the…
- Conditions
- MASH - Metabolic Dysfunction-Associated Steatohepatitis, MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease), Fibrosis and Cirrhosis of Liver, MetALD
- Trial name
- NCT07867574
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Active Genomes Expressed Diagnostics, Corp
Metabolic Dysfunction Associated Fatty Liver Disease
Effect of High Protein Diet on Hepatic Steatosis in Patients With MAFLD
MAFLD is a growing problem in India. Its pathophysiology is complex, but focused on abnormal substrate handling due to mitochondrial dysfunction reflecting as metabolic inflexibility. Nutrition is the cornerstone of management.
- Trial name
- NCT06749704
- Testing
- High protein diet, Normal Protein diet
- Where
- India
- Volunteers
- 140 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Metabolic Dysfunction-associated Steatotic Liver Disease
Guerbet Liver Fibrosis
The goal of this study is to assess the value of liver dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and texture analysis post gadopiclenol for liver fibrosis staging, in comparison with MR elastography, T1…
- Trial name
- NCT06703450
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Icahn School of Medicine at Mount Sinai
Non-Alcoholic Fatty Liver Disease
Diet and Meal Timing in Patients With Metabolic Dysfunction Associated Steatoic Liver Disease
This study will assess the impact of time-restricted eating (8 hours of eating each day) with standard of care lifestyle recommendations (hypocaloric, Mediterranean diet and 30 minutes of exercise on at least 5 days/week) on the…
- Trial name
- NCT05332613
- Testing
- TRE plus SOC, SOC, TRE
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Weill Medical College of Cornell University
Fatty Liver, NAFLD
Effect of CoQ10 on the Outcome of MAFLD Patients
So far there has been no universal treatment for MAFLD since it has a complex etiology that involves ethnic, genetic, metabolic and environmental factors.
- Trial name
- NCT05984745
- Testing
- Coenzyme Q10 Forte® capsules
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Ain Shams University
Metabolic Dysfunction-Associated Steatotic Liver Disease, Type 2 Diabetes (T2DM)
The Establishment of Hong Kong Diabetes Steatotic Liver Disease Register
Liver is an important organ in maintaining energy homeostasis. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), is the most common chronic liver…
- Trial name
- NCT07437157
- Testing
- No intervention (observational study)
- Where
- Hong Kong
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Chinese University of Hong Kong